Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: Cancer Prev Res (Phila). 2011 Aug 31;4(12):2083–2091. doi: 10.1158/1940-6207.CAPR-11-0319

Figure 4.

Figure 4

CPT inhibition of LEC tube formation is through targeting VEGFR-3-mediated ERK1/2 pathway. A, B, Expression of constitutively active MKK1 attenuated CPT inhibition of ERK1/2 phosphorylation and the tube formation in LECs. LECs, infected with Ad-MKK1-R4F and Ad-GFP (control), respectively, were treated with or without CPT (10 µM) for 24 h, followed by Western blotting with indicated antibodies (A), or by tube formation assay (B) as described in “Materials and Methods”. Quantitative results are shown as mean ± SD (n = 3). *P < 0.05, difference vs. control group; #P < 0.05, difference vs. Ad-GFP group. C, D, LECs were treated with U0126 (2.5 µM) or CPT (5 µM) alone, or both for 24 h, followed by Western blotting using the indicated antibodies (C), or by tube formation assay (D) as described in “Materials and Methods”. Quantitative results of tube formation are shown as mean ± SD (n = 3). *P < 0.05, difference vs. control group. #P < 0.05, difference vs. U0126 or CPT treatment group.